title: Long-term efficacy and safety of fosamprenavir in human immunodeficiency virus-infected pediatric patients.
abstract: Fosamprenavir (FPV) efficacy in human immunodeficiency virus (HIV)-infected pediatric patients is still being evaluated in ongoing clinical trials. The long-term efficacy and safety of FPV boosted with ritonavir (FPV/r) was evaluated in 20 antiretroviral-naive and antiretroviral-experienced HIV-vertically infected pediatric patients. Analyses of CD4(+) T-cells, HIV-ribonucleic acid (RNA), and clinical status were performed during a median of 180 weeks. Initially, median HIV-RNA was 4.6 log(10) in naive and 4.4 log(10) in pretreated patients. Median CD4(+) T-cell was 17% and 31%, respectively. After FPV/r treatment, 18 of 20 patients achieved undetectable HIV-RNA and 4 of 20 experienced adverse events. To date, FPV/r treatment has shown sustained antiviral response and immunologic improvement in our 20 patients.
authors.affiliation: Laboratorio de Inmuno-Biología Molecular, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
authors.forename: Claudia
authors.initials: C
authors.lastname: Palladino
authors.forename: Verónica
authors.initials: V
authors.lastname: Briz
authors.forename: Sergio Negre
authors.initials: SN
authors.lastname: Policarpo
authors.forename: Laura Fernandez
authors.initials: LF
authors.lastname: Silveira
authors.forename: M Isabel
authors.initials: MI
authors.lastname: de José
authors.forename: M Isabel
authors.initials: MI
authors.lastname: González-Tomé
authors.forename: David
authors.initials: D
authors.lastname: Moreno
authors.forename: Juan A
authors.initials: JA
authors.lastname: León Leal
authors.forename: M José
authors.initials: MJ
authors.lastname: Mellado
authors.forename: Santiago J
authors.initials: SJ
authors.lastname: de Ory
authors.forename: José T
authors.initials: JT
authors.lastname: Ramos
authors.forename: M Angeles
authors.initials: MA
authors.lastname: Muñoz-Fernández
mesh_terms: D000293:Adolescent; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D018791:CD4 Lymphocyte Count; D002219:Carbamates / Q000008:administration & dosage* / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005663:Furans; D006678:HIV / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1; D006801:Humans; D008297:Male; D010755:Organophosphates / Q000008:administration & dosage* / Q000009:adverse effects*; D012367:RNA, Viral / Q000032:analysis; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D013449:Sulfonamides / Q000008:administration & dosage* / Q000009:adverse effects*; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D002219:Carbamates; D005663:Furans; D010755:Organophosphates; D012367:RNA, Viral; D013449:Sulfonamides; C426859:fosamprenavir